Europe Pancreatic Cancer Diagnostics Market - Industry Trends and Forecast to 2030

The Europe pancreatic cancer diagnostics market is projected to register a substantial CAGR of 7.6% from 2023 to 2030. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2023 to 2030.

Market Segmentation: 
Europe Pancreatic Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Blood Test, Genomic Test, and Others), Cancer Stage (Stage 0, Stage I, Stage II, Stage III and Stage IV), Tumor Type(Exocrine Tumors and Neuroendocrine Tumors), Product (Instrument-Based Products, Platform-Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application(Screening, Diagnostic and Predictive, Prognostic, and Research), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales and Others), Country (Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland and the Rest of Europe) Industry Trends and Forecast to 2030

Some of the major factors contributing to the growth of pancreatic cancer diagnostics market are:
• Rise in prevalence and incidence of pancreatic cancer 
• Increase in awareness about the pancreatic cancer diagnostics

Market Players:

Some of the major players operating in the Europe pancreatic cancer diagnostics market are:

• Canon Medical Systems ANZ Pty Limited.
• Koninklijke Philips N.V.
• Siemens Healthcare Private Limited
• Grail
• Myriad Genetics, Inc.
• BD
• Abbott
• Agilent Technologies, Inc.
• Thermo Fisher Scientific
• QIAGEN 
• MP BIOMEDICALS
• Laboratory Corporation of America Holdings
• DiaSource 
• Creative Biolabs
• Meridian Life Science, Inc.